在实验中用3-羟基吡啶乙酰半胱氨酸和3-羟基吡啶琥珀酸酯评估纠正阿霉素诱导的慢性心力衰竭的可能性。
Evaluation of the Possibility of Correction of Doxorubicin-Induced Chronic Heart Failure in the Experiment with 3-Hydroxypyridine Acetylcysteinate and 3-Hydroxypyridine Succinate.
作者信息
Zamotaeva M N, Inchina V I, Konorev V V, Kuznetsov Yu V, Kuz'michev N D
机构信息
N. P. Ogarev Mordovian National Research State University, Saransk, Republic of Mordovia, Russia.
N. M. Emanuel Institute of Biochemical Physics, Moscow, Russia.
出版信息
Bull Exp Biol Med. 2018 Jul;165(3):344-346. doi: 10.1007/s10517-018-4166-y. Epub 2018 Jul 13.
The possibility of correction of morphological changes in the myocardium and biochemical parameters of the blood with 3-hydroxypyridine acetylcysteinate in a dose of 25 mg/kg was studied in the model of doxorubicin-induced chronic heart failure in rats. It was found that 3-hydroxypyridine acetylcysteinate in a dose of 25 mg/kg produced less pronounced cardio-protective effect in experimental chronic heart failure than 3-hydroxypyridine succinate.
在阿霉素诱导的大鼠慢性心力衰竭模型中，研究了剂量为25mg/kg的3-羟基吡啶乙酰半胱氨酸对心肌形态学变化和血液生化参数的改善可能性。结果发现，与3-羟基吡啶琥珀酸盐相比，剂量为25mg/kg的3-羟基吡啶乙酰半胱氨酸在实验性慢性心力衰竭中产生的心脏保护作用较弱。
Zotero 插件